|
|
Post by cyn on Aug 4, 2017 9:08:50 GMT -5
A couple thoughts/questions... Being an "unmasked" study won't the sponsors have immediate access to patient-specific data? And, if the magnitude of response is overwhelmingly superior, couldn't the sponsors make this data available to the FDA and/or MNKD early-on before any scheduled readouts? And, if so, couldn't this benefit MNKD is negotiating partnerships and financing?
|
|
|
|
Post by mnholdem on Aug 4, 2017 9:12:52 GMT -5
Good point! We see biotechs stock prices pop all the time upon release of preliminary trial results.  |
|
|
|
Post by peppy on Aug 4, 2017 9:20:12 GMT -5
afrezza. timing is everything.
we will see.
recommend follow-on doses. For example, we advise with a standard meal to dose Afrezza 15-20
minutes after the start of the meal, and then another dose of the same size about 45 minutes later.
With very long meals, we have even advised patients to administer two follow-on doses, for very tight control.
www.seventhform.com/vdexdownloads/vdex-whitepaper-072817.pdf page 22.
|
|
